Mandate

Vinge has assisted Novozymes Biopharma DK A/S

November 08, 2011

Vinge has assisted Novozymes Biopharma DK A/S in the sale of Novozymes Biopharma Sweden AB to Repligen Corporation. Novozymes is the world leader in bio innovation with industrial enzymes, microorganisms, and biopharmaceutical ingredients as its business. Novozymes generated sales of DKK 9,724 million and EBIT of DKK 2,117 million in 2010.

Repligen Corporation is a leading supplier of critical technologies and ingredients used to manufacture biologic drugs. Repligen's corporate headquarters are in Massachusetts, USA.

Vinge’s team has primarily consisted of Björn Mullaart (partner), Karin Ebbinghaus (senior associate and Karin Engström (associate).

Proposal for a European Media Freedom Act

The European Commission has presented a proposal for new legislation which aims to protect journalists and media companies and combat disinformation.
September 26, 2022

The European Commission proposes a new Single Market Emergency Instrument

On 19 September 2022, the Commission adopted a proposal for a new regulation on an emergency instrument for the Single Market. Following the Covid-19 pandemic and other crises in the last years, the Union has seen internal entry restrictions, unpredictable rules and supply disruptions which, according to the Commission, have highlighted that there are structural shortcomings in the EU legal framework on the Single Market. The proposed emergency instrument aims to preserve the free movement of goods, services and persons and to ensure the availability of essential goods and services in the event of future emergencies.
September 22, 2022

New partners and counsels appointed at Vinge’s Gothenburg office

Ninos Aho has been appointed partner at Vinge’s Gothenburg office, as of 1 January 2023. In addition, advokat Petronella Hallberg and advokat Martin E Svanberg have been appointed as counsels, also as of 1 January 2023.
August 30, 2022